AVI Biopharma’s Chief Science Officer To Resign
Drug developer AVI Biopharma Inc. said Thursday that Chief Scientific Officer Peter Linsley will resign from the company.
avi biopharma
Shire, Acceleron to Collaborate on Treatments for Rare Muscle Diseases
Shire Pharmaceuticals has signed a $498 million collaboration agreement with Acceleron Pharma to develop and commercialize treatments for muscular and neuromuscular disorders.